Article Figures & Data
Figures
- Fig. 1.
Pharmacokinetics of V-073 in mice (Cmax, ng/ml; AUC24, ng·h/ml).
- Fig. 2.
Schedules of immunization and antiviral treatment.
- Fig. 3.
Percentage of animals in which serum-neutralizing antibody response was elicited by IPV administered to untreated mice and mice administered vehicle or various doses of V-073 (1, 3, 10, and 30 mg/kg) at the time of primary vaccination (A) or booster immunization (B). The response was assessed on days 20 (before booster), 28 (7 days after booster), and 35 (14 days after booster).
- Fig. 4.
Serum-neutralizing (SN) antibody titers elicited by IPV in untreated mice (NT) and mice administered vehicle (V) or various doses of V-073 (1, 3, 10, and 30 mg/kg) at the time of primary vaccination (A) or booster immunization (B). Median titers are indicated by the solid line in each column, and geometric mean titer (GMT) values are provided below for each indicated group.
